Skip to main content
NCBI home page
Cell Death Discovery logoLink to Cell Death Discovery
. 2022 Aug 22;8:370. doi: 10.1038/s41420-022-01164-5

Transcriptional and genetic alterations of cuproptosis-related genes correlated to malignancy and immune-infiltrate of esophageal carcinoma

Runmin Jiang 1,2,#, Yu Huan 3,#, Yan Li 4,#, Xinyue Gao 5, Qiang Sun 5,✉, Feng Zhang 2,✉, Tao Jiang 1,✉
PMCID: PMC9395517  PMID: 35995782

Abstract

Esophageal carcinoma (ESCA) is a common type of cancer with high mortality. Cuproptosis is a new type of cell death and is characterized by the dependence on mitochondrial respiration and protein lipoylation. However, the potential roles of cuproptosis-related genes (CRGs) in ESCA remain elusive. Here, we systematically assessed the transcriptional and genetic alterations of CRGs in ESCA. We identified a CRGs signature for ESCA patients. A 6-CRGs signature was constructed by the least absolute shrinkage and selection operator (LASSO) regression analysis along with the univariate cox regression analysis and differential genes analysis. The CRGs score could significantly stratify ESCA patients’ survival and a high CRGs score was significantly correlated with worse overall survival. Moreover, higher CRGs score indicated higher pathology grades and aberrant cell adhesion, possibly via the PI3K-AKT pathway, which could also underly their increased sensitivity to PI3K-AKT pathway inhibitors. In addition, patients with high CRGs tend to hold more mutation load and abnormal APOBEC mutation. Notably, a higher CRGs score was anomalously associated with more immune infiltration, which could explain its malignancy by increased PD-L1 stability and a higher proportion of bystander T cells. In conclusion, our report revealed the significance of cuproptosis in ESCA and may have therapeutic potential in activating the bystander T cells.

Subject terms: Oesophageal cancer, Tumour immunology

Introduction

Esophageal carcinoma (ESCA) is one of the most common cancers worldwide, ranking seventh in morbidity and sixth in mortality among all cancers [1, 2]. Due to the lack of early diagnosis, most patients (~75%) are diagnosed at late stages, which resulted in only about 20–25% five-year survival rate for decades without great improvement [3]. Thus, a more useful prognostic biomarker, and therapeutic strategy as well, is still a pressing need.

Copper is one of the most important metals in bioactivities. Cells have to maintain a modest copper concentration for survival and function normally. It would result in life-threatening diseases once the copper homeostasis was dysregulated such as genetic variation [4, 5]. The function of key metal-binding enzymes will be damaged in a low copper concentration. On the contrary, the threshold-exceeded accumulation of copper would also be toxic and lead to cell death [6]. Cuproptosis is a new type of cell death and is characterized by the dependence on mitochondrial respiration and protein lipoylation, which is distinct from known death mechanisms, including apoptosis, ferroptosis, pyroptosis, necroptosis, and non-cell-autonomous death mediated by cell-in-cell structures [6–12]. Once overloaded, copper would bind directly to lipoylated components of the tricarboxylic acid (TCA) cycle, which leads to lipoylated protein aggregation and subsequent loss of iron-sulfur cluster protein. This would contribute to proteotoxic stress, ultimately resulting in cell death [6].

Accumulating evidence indicates the crosstalk between cuproptosis and cancer. Elesclomol, a molecule that binds copper in the environment and brings it into the cell to induce cell death, has been employed in human clinical trials for epithelial cancer therapy [13]. According to Tsvetkov’s reports, elesclomol was supposed to work best in cancers with up-regulation of lipoylated mitochondrial proteins and highly respiratory, which was supposed to be especially useful for cancers that are naturally resistant to apoptosis [6]. However, the applications of cuproptosis in ESCA were yet to be explored.

Here, by comprehensive analysis of the cuproptosis-related genes (CRGs) in ESCA, we reported that the higher GSVA score of the cuproptosis pathway indicates the progression of ESCA cells such as higher pathology grades and aberrant cell adhesion, possibly via the PI3K-AKT pathway. We showed a positive correlation between PI3K-AKT pathway inhibitors sensitivity and CRGs expression in ESCA cells. Additionally, we developed a CRGs signature as a promising prognostic model by the least absolute shrinkage and selection operator (LASSO). The higher CRGs score suggested a bad survival ending while a more immune infiltration in ESCA, which could be explained by the increased stability of PD-L1 and the increased proportion of bystander T cells. Our analysis revealed the significance of cuproptosis in ESCA and may have therapeutic potential in activating the bystander T cells in ESCA.

Results

The transcriptional and genetic landscape of cuproptosis-related genes (CRGs) in ESCA

Firstly, we collected a total of 25 CRGs for analysis based on the cuproptosis pathway and Genecard database (Table S1). In order to further explore the expression correlations of CRGs, we conducted a correlation analysis and showed the results in Fig. 1A, respectively. To investigate the global expression of CRGs, we compared the expression level of CRGs between the normal and ESCA samples. Heatmap revealed an increased overall expression level of CRGs in ESCA samples (Fig. 1C). In line with this, although there was no significance of GSVA scores among the different grades, it still revealed an increased tendency of GSVA scores in the higher grades in ESCA (Fig. 1D, E).

Fig. 1. The transcriptional and genetic alterations of cuproptosis-related genes in esophagus carcinoma.

Fig. 1

Open in a new tab

A The correlations between the expression of cuproptosis-related genes (CRGs). B Mutation frequencies of 25 CRGs in 173 patients with esophagus carcinoma (ESCA). C The heatmap showed the expression level and clinicopathologic features of 25 cuproptosis-related genes between normal and ESCA samples. D, E Differences (D) and tendency (E) in GSVA score of 25 CRGs in ESCA samples with different pathology grades. Data was exhibited as mean ± SD. Significance was assessed by Pearson’s correlation test (A), and KruskalWallis test (D). ns = not significant, *P < 0.05; **P < 0.01; ***P < 0.001.

Identification of candidate prognostic CRGs

Next, we explored the relationship between the CRGs expression and patients’ survival. From the 25 CRGs, eight genes SLC25A5, SLC23A2, PDHX, COX7B, PIH1D2, FDX1, ATP7A, NDUFB1 (SLC25A5, SLC23A2, PDHX, COX7B, PIH1D2, FDX1, ATP7A, and NDUFB1) were ultimately filtered to be associated with prognosis using LASSO regression analysis (Fig. 2A, B, Table S2). Meanwhile, univariate Cox regression analysis and Kaplan–Meier survival curves were further utilized to assess the significance of the eight CRGs expression on the prognosis of ESCA patients. As shown in Fig. 2C, D, the higher expression of SLC25A5, SLC23A2, PDHX, ATP7A, and COX7B predicted a bad survival ending (P < 0.05) while patients would obtain a longer survival when the expression of PHID2 was higher (P < 0.05).

Fig. 2. Identification of candidate prognostic CRGs.

Fig. 2

Open in a new tab

A, B LASSO analysis filtered out the candidate prognostic CRGs of the 25 CRGs. C Univariate Cox analysis of the candidate prognostic CRGs. D The Kaplan-Meier curves of the candidate prognostic CRGs for ESCA patients. Significance was assessed by a log-rank test (B).

Construction and validation of a minimal CRGs signature that predicted the survival of ECSA patients

In order to further confirm the expression levels of the eight genes, we visualized their mRNA expression levels and found the expression of SLC23A2, PDHX, COX7B, and ATP7A up-regulated in tumor, while the expression of the other showed no significant difference (Fig. 3A). Consistently, the representative immunohistochemical staining images of these genes from The Human Protein Atlas also showed a similar expression trend (Fig. 3B). We, therefore, selected the six genes (SLC25A5, SLC23A2, PDHX, COX7B, ATP7A, PIH1D2) as the minimal CRGs and the corresponding risk score formula was as follows: Risk score = 0.22863 × expression of SLC25A5 + 0.18401 ×expression of SLC23A2 + 0.33753× expression of PDHX + 0.28295 × expression of COX7B + 0.23044 ×expression of ATP7A -0.02041 × expression of PIH1D2. 95 patients were assigned to the high CRGs-score group, and the other 44 patients were assigned to the low CRGs -score (Fig. 3C). Notably, the 6 CRGs signature could significantly stratify ESCA patients into two prognostic groups with high scores predicting shorter overall survival (Fig. 3C). Consistently, the 3-, 4-, and 5-year ROC curves demonstrated that the CRGs-signature held a good prediction performance (p < 0.05, AUCmax = 0.9, Fig. 3D)

Fig. 3. Construction of the minimal CRGs signature that predicted the survival of ECSA patients.

Fig. 3

Open in a new tab

A Differential gene expression of the prognostic CRGs between normal samples and ESCA samples. The data was from the GEPIA2 database. B Representative images showed the differential protein level of the prognostic CRGs between normal samples and ESCA samples. The data was from The Human Protein Atlas database. C Kaplan-Meier survival curves of the CRGs- signature in ESCA patients. D The 3-, 4-, and 5-year ROC curves for CRGs- signature in ESCA patients. Data was exhibited as mean ± SD. Significance were assessed by Wilcoxon test (A) and log-rank test (C). ns = not significant, *P < 0.05; **P < 0.01; ***P < 0.001.

Association of high CRGs score with abnormal cell adhesion and PI3K-AKT pathway

To investigate the genes and pathways that underlie the survival difference, we firstly identified the differential genes between the high and low CRGs-score groups. Except for CRGs (SLC25A5, COX7B), AMBP, AIFM1, MAP7D1, TSHZ3, CAV1, et al. showed a significant difference (Fig. 4A). Further KEGG along with the GSEA analysis revealed that the differential genes between high and low CRGs group were mainly involved in the regulation of ECM receptor, focal adhesion, cell adhesion, and PI3K-AKT signaling pathway (Fig. 4B). Thus, we suppose that the different survival endings of two CRGs-score groups may ascribe to the aberrant function in cell adhesion, which possibly results from the activation of PI3K-AKT signaling.

Fig. 4. Higher CRGs score was related to abnormal cell adhesion via the Akt-PI3K pathway.

Fig. 4

Open in a new tab

A Differentially expressed genes (DEGs) between the high-CRGs score group and the low-CRGs score group. B KEGG enrichment analyses of DEGs between high-CRGs score group and low-CRGs score group. C GSEA enrichment analyses of DEGs between high-CRGs score group and low-CRGs score group.

Association of high expression of CRGs with TGX221 sensitivity

To investigate the potential drugs for ESCA therapy, we used the Genomics of Drug Sensitivity in Cancer (GDSC) database to assess the relationship between CRGs and drug sensitivity. As shown in Fig. 5A, higher expression of COX7B was correlated with higher sensitivity of various drugs, such as Bleomycin, TGX221, and Dasatinib. Similarly, there are also positive correlations between the SLC25A5 or PIH1D2 expression and the drug sensitivity. Consistent with the Fig. 4B, among these drugs, TGX221 and SB 216763 were the PI3K-AKT pathway inhibitors, which showed a great positive correlation with COX7B or SLC25A5 expression. Thus, we selected the TGX221 for further experiments. To validate the positive correlations between TGX221 and COX7B, we transfected si-COX7B into EC109 cells and then verify the efficiency by qRT-PCR (Fig. 5B). Next, we treated si-Con1 EC109 cells and si-COX7B EC109 cells with a gradient dose of TGX221 and found that si-COX7B EC109 cells showed more cell viability when treated with TGX221, indicating its lower sensitivity (Fig. 5C). Similar results were also observed in si-SLC25A5 EC109 cells (Fig. 5D, E).

Fig. 5. Higher expression of CRGs was related to more drug sensitivity.

Fig. 5

Open in a new tab

A The correlations between the drug sensitivity and CRGs expression. B, C qRT-PCR analysis verified the efficiency of COX7B (B) and SLC25A5 (C) knockdown in EC109 cells. D Cell viability between EC109 cells transfected with si-Con1 and si-COX7B when treated with a gradient dose of TGX221 (n = 5). E Cell viability between EC109 cells transfected with si-Con2 and si-SLC25A5 when treated with a gradient dose of TGX221 (n = 5). Data was exhibited as mean ± SD. Significance were assessed by two-tailed t-test (D, E). ns = not significant, *P < 0.05; **P < 0.01; ***P < 0.001.

A high mutation load in patients with high CRGs score

We then explore the genetic alterations in the two CRGs-score groups by taking advantage of the TCGA database. As shown in Fig. 6A–D, patients with high CRGs score obtained a higher loading of various variant classifications and types (missense mutation, frameshift deletions, nonsense mutation, SNP, INS, DEL). The top ten mutated genes in the high group are TP53, TTN, MUC16, SYNE1, LRP1B, DNAH5, PCLO, FAT3, HMCN1, CSMD3, and the low group has TP53, TTN, KMT2D, CSMD3, MUC16, SYNE1, PCDH15, FLG, NOTCH1, COL6A5 (Fig. 5E). Patients with high CRGs score had markedly higher frequencies of TP53(81%), and TTN (49%) mutations compared to TP53(75%), and TTN (30%) in the low CRGs-score group. Moreover, LRP1B, DNAH5, PCLO, FAT3, HMCN1 mutations were seems to be peculiar to high CRGs core patients, indicating their association with the CRGs and worse bio-activities in ESCA (Fig. 6E).

Fig. 6. Higher CRGs score patients held a higher mutation loading.

Fig. 6

Open in a new tab

A Variant classification graph between high-CRGs score group and low-CRGs score group. B Variant type graph between high-CRGs score group and low-CRGs score group. C SNV class graph between high-CRGs score group and low-CRGs score group. D Variation per sample between high-CRGs score group and low-CRGs score group. E Variant classification summary graph between high-CRGs score group and low-CRGs score group. F Top 10 mutated genes between high-CRGs score group and low-CRGs score group.

APOBEC family mutation landscape in two CRGs-score groups

APOBEC (apolipoprotein B mRNA-editing enzyme catalytic polypeptide) is a family of cytidine deaminase, whose transcription can be activated by pro-inflammatory cytokines and chemokines [14]. It was found that the APOBECs family could drive the formation of cancer-promoting virus mutants. Its gene coding function could also induce cancer-promoting driving mutation which plays a bridge role in inflammation-cancer transformation [15, 16]. In the high CRGs score group, the mutation load between APOBEC-enriched and non-enriched samples showed no significance and the TCW loading rate (C > T and C > G mutations at T-C-A/T trinucleotides) in APOBEC-enriched samples was 0.28, which was lower than that in low CRGs score group (0.32). However, many mutated APOBEC genes in the high CRGs score group (no less than 10) were higher than the only 3 mutated APBEOC genes in the low CRGs group, which may also underly the tumor progression in the high CRGs score group (Fig. 7A, B).

Fig. 7. APOBEC family mutation landscape in two CRGs -score groups.

Fig. 7

Open in a new tab

A The mutation load and tCw load between the APOBEC and non-APOBEC enriched samples in the high-CRGs score group. B The mutation load and tCw load between the APOBEC and non-APOBEC enriched samples in the low-CRGs score group. Data was exhibited as mean ± SD. Significance were assessed by Wilcoxon test (A, B). ns = not significant, *P < 0.05; **P < 0.01; ***P < 0.001.

Association of high CRGs score with immune infiltration, PD-L1 stability, and an increased proportion of bystander T cells

To investigate the immune infiltration status between high and low CRGs score groups, we next performed ssGSEA analysis of immune cells-related genes to assess the association between CRGs score and the infiltration of immune cells. Unexpectedly, as shown in Fig. 8A, the heat map of immune cells exhibited a much more infiltration in the high CRGs-score group, such as activated CD4 + T cells, activated CD8 + T cells, memory T cells, and NK cells. Given that the high- CRGs score implies a bad survival ending, it seems that more infiltration could not explain it well. To solve this problem, we investigated the immune activation status by comparing the expression of CD8A, CXCL9, CXCL10, GZMA, GZMB, PRF1, and IFHG, TBX2, and TNF. As expected, the immune activation status showed no difference between the high and low CRGs score group (Fig. 8B). In addition, although the immune checkpoints genes such as PD-L1 expression were downregulated in the higher CRGs group, the stability of PD-L1 was upregulated in these samples due to the upregulation of CMTM6 and CMTM4, which could prevent PD-L1 from being targeted for lysosome-mediated degradation [17] (Fig. 8C, D). Furthermore, the down-regulation of CD39 also suggests a higher proportion of bystander T cells, which may underly this problem as well (Fig. 8E). Next, we checked the tumor mutation burden (TMB) score to evaluate the PD-L1 effect on ESCA. Although there was no difference between the high and low CRGs score group, the high CRGs-score group appeared to hold a higher TMB score (Fig. 8F). Consistently, it was also found in the ICVRG2010 cohort that the CRGs expression (COX7B, PDHX) in PD-L1 response patients was higher than in non-response patients, indicating a preferable curative potency and better survival ending for patients with higher CRGs score when treated with PD-L1 (Fig. 8G). Taken together, these results revealed that a high CRGs score was associated with higher immune infiltration and bystander T cells, and patients may be more responsive to anti-PD-L1 therapy.

Fig. 8. Higher CRGs score was associated with more immune infiltration, PD-L1 stability, and more proportion of bystander T cells.

Fig. 8

Open in a new tab

A The heatmap showed the immune infiltration status between the high-CRGs score group and the low-CRGs score group. B Expression of immune activation genes between high-CRGs score group and low-CRGs score group. C Expression of immune checkpoint genes between high-CRGs score group and low-CRGs score group. D Expression of PD-L1 stability genes (CMTM6, CMTM4) between high-CRGs score group and low-CRGs score group. E Expression of bystander T cell genes (CD39) between high-CRGs score group and low-CRGs score group. F Tumor mutation burden (TMB) score between high-CRGs score group and low-CRGs score group. G Expression of CRGs between response and non-response patients that received PD-L1 inhibitor treatment in the IMvigor210 (mUC) cohort. Data was exhibited as mean ± SD. Significance were assessed by two-tailed t-test (B–G). ns = not significant, *P < 0.05; **P < 0.01; ***P < 0.001.

Discussion

Previous studies suggested aberrant copper homeostasis (ACH) was highly associated with cancers such as bladder cancer, breast cancer, colorectal cancer, and prostate cancers [18–21]. Supporting this, in carcinogenesis, ACH was observed to contribute to the proangiogenic response via various molecular pathways, which played a fundamental role in cancer proliferation or angiogenesis [22]. Moreover, copper accumulation in cancer cells was also reported [23, 24].

Here, we systematically investigate the role of the cuproptosis-related genes in the prognosis, pathways, and immune infiltration of ESCA. By performing LASSO analysis along with exploration of their differential expression in mRNA and protein level, we identified a 5 CRGs signature. The KM curve suggested that the CRGs signature could stratify overall survival efficiently.

SLC25A5, SLC23A2, PDHX, COX7B, ATP7A, and PIH1D2 were filtered out to construct the CRGs signature, which was rather reasonable. SLC25A5 was identified as a biomarker in clear cell renal cell carcinoma involving competitive endogenous RNA [25]. SLC23A2(SVCT2), which takes the function to reduce the oxidative damage caused by copper overloaded [26, 27], was reported to be a polymorphism in gastric cancer or chronic lymphocytic leukemia [28, 29]. PDHX, which takes part in encoding the pyruvate dehydrogenase (PDH) complex, was deficient in human breast tumor samples, and low levels of PDHX were also associated with decreased patient survival [30]. Consistently, in nasopharyngeal carcinoma (NPC), COX7B was found to hold a high positive rate (84.24%) in tumor samples and was thought to be a putative molecular marker in NPC [31]. PIH1D2 was reported to be deleted in paragangliomas [32].

Our reports revealed that CRGs was also associated with the grading of ESCA. On one hand, the high grades samples of ESCA appeared to hold a higher GSVA score of CRGs (Fig. 1 C, D). On the other, the differential genes between high and low CRGs-score groups showed enrichment in extracellular matrix interaction and focal adhesion function, suggesting an aberrant cell adhesin in high CRGs score samples. Consistent with our reports, Cu concentration was also found to increase in tumor areas and even correlated with the grade of cancer [33–35]. High serum Cu levels were also found in cancer patients resistant to chemotherapy compared to patients responding to treatment [35] and promote the scatter and formation of secondary tumors by activating cell proliferation-related enzymes [22].

Interestingly, in our analysis, patients with high CRGs score gained more immune infiltration while a bad survival ending. Although the immune-escaping genes such as PD-L1(CD274), and LAG3 in high CRGs score patients were downregulated, the PD-L1 would be more stable in these patients due to the high expression of CMTM4, which is regarded as the PD-L1 stabler. Consistent with our reports. Zhou B also found that Cu ionophore disulfiram can induce stabilization of PD-L1 by overloading cancer cells with Cu [36]. Moreover, bystander T cells were often observed in cancers, such as lung cancer and colon cancer, which represented a poor immunotherapy response [37, 38]. Here, we found the CRGs score could filter patients with bystander T cells, due to the high CRG score patients held the lower expression of CD39 (ESPDN1), the marker of bystander T cells [37, 38]. Nonetheless, the relationship between cuproptosis and the bystander T cells should be further explored.

In conclusion, our study comprehensively explored the expression profiling and mutation landscape of cuproptosis-related genes in ESCA. By constructing the cuproptosis-related genes (CRGs) signature, we reported that a higher CRGs score represented the progression of ESCA, because worse survival outcomes, higher pathology grades, aberrant cell adhesion and APOBEC mutation loading were found in patients with high CRGs scores. In addition, higher CRGs score patients tend to hold more immune infiltration, which we analyzed that the higher proportion of bystander T cells and the more stable PD-L1 expression would underlie it. Our results provide a new prognostic predictor and offer novel insights into the clinical application of cuproptosis and immune checkpoints targeting therapies.

Materials and methods

Data source

The CRGS were collected from Tsvetkov’s reports [6] and Genecard. A total of 25 CRGs were included in this study (Table S1). The gene expression data and clinical data were downloaded from The Cancer Genome Atlas database (TCGA) up to March 1, 2022 (https://portal.gdc.cancer.gov). A total of 174 samples were collected, including 11 normal samples and 163 tumor samples. Transcripts per million (TPM) of gene expression data was utilized for further analysis. The clinical data includes the age, clinical stages, pathology grades, and Barrett’s esophagus.

GEPIA2 was used to compare the expression levels of genes between normal and tumor samples. Human Protein Atlas (HPA) was utilized to compare the expression level of the protein between normal and tumor samples.

The mutation annotation format (MAF) data of ESCA was downloaded from the UCSC Xena server and analyzed with the “maftools” R package. Oncoplot was drawn according to the descending order of mutations.

To compare the gene expression between response and non-response patients treated with a PD-L1 inhibitor, the data of the IMvigor210 (mUC) cohort from patients with mUC receiving PD-L1 inhibitor treatment were collected. The expression data and clinical data were obtained from the IMvigor210 (mUC) dataset (http://research-pub.gene.com/IMvigor210CoreBiologies) with the ‘IMvigor’ package in R.

Construction of the CRGs signature

To reduce the risk of over-fitting, the least absolute shrinkage and selection operator (LASSO) with 10-fold cross-validation was performed with the “glmnet” R package screening for CRGs related to overall survival as described [39]. Next, univariate Cox regression analysis were conducted to assess whether this risk score model displayed good predictive ability for prognosis. Then, CRGs with no significance in their expression between normal and ESCA tumors were excluded. Next, The CRGs-score of each patient was calculated based on the amount of calculated gene expression and the corresponding coefficient. The formula was as the following:

CRG_score=∑Expi*coefi

where Expi and Coefi represented the expression of each gene and the risk coefficient, respectively. Next, we classified the patients into high-risk group and low-risk group according to the optimal cutoff value of risk score that was analyzed by the R package “survival”. Kaplan–Meier analysis was carried out to explore the prognostic significance of the CRGs signature in ESCA by the “ggsurvplot” package. Then, to assess the predictive efficiency of the CRGs-signature, receiver operating characteristic (ROC) of 5-year survival was performed with the “survivalROC” package in the TCGA-ESCA cohort.

Differential genes exploration and gene set enrichment analysis

Differential genes between the high CRGs score and low CRGs score group were identified by the “limma” package in R with the criterion of |log2(fold change) | > 0.5 and adjusted p value < 0.05.

Furthermore, we performed the Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment analysis and gene set enrichment analysis (GSEA) of CRGs with the R package “clusterProfiler”. P < 0.05 and the false discovery rate (FDR q) < 0.05 was considered statistically significant.

Evaluation of chemotherapeutic drug sensitivity

Genomics of Drug Sensitivity in Cancer (GDSC) (https://www.cancerrxgene.org/) were used to explore the relationship between mRNA expression level and drug sensitivity. To be specific, the IC50 of small molecules in various cell lines and the mRNA gene expression were obtained from GDSC. Then, Pearson analysis was carried out to evaluate the correlation between gene expression and IC50. P-value was adjusted by FDR.

Cell culture

The human esophagus carcinoma cell line (ECA-109) was obtained from the American Type Culture Collection (ATCC). The identity of the EC109 cell line was validated to be correct by Short tandem repeat (STR). Cells were cultured with DMEM (Gibco, ThermoFisher Scientific, Waltham, USA) medium supplemented with 10% fetal bovine serum, 50 μg ml−1 streptomycin, 100 units ml-1 penicillin, (Gibco), and incubated at 37 °C with 5% CO2.

Cell transfection

siRNA of candidate genes and the control si-Con were commercially purchased from Tsingke (Tsingke Biotechnology Co., Ltd., Beijing, China). Cells were transfected according to the protocols of the ViaFect™ (Promega, Wisconsin, USA). The sequences of siRNA were shown in Table S2

RNA isolation and quantitative real-time PCR

Total cellular RNA was extracted using the TRIzol reagent (Invitrogen, Carlsbad, CA, USA). The Complementary DNA (cDNA) was synthesized with the PrimeScript RT reagent kit (Takara, 6210, China). The RT-qPCR was performed with SYBR Green Supermix (Bio-Rad, 172-5850, USA). The gene expression levels data were calculated using the 2-ΔΔC t method, normalized with GAPDH expression levels. The primer sequences used are listed in Table S3.

Drug sensitivity measurements

Drug sensitivity was determined using the cell counting kit-8 assay (CCK-8 assay kit, Bimake, Houston, USA). Cells were seeded in 96-well plates at a density of 5000 cells per well and cultured overnight for adhesion. Then, gradient doses of TGX221(Selleck, USA, Texas) were added to the culture medium for 24 h. Next, 2 h after 10 µl of CCK-8 administration per well, the optical density was measured at 450 nm with a microplate reader with a spectrophotometer (Mutiskan Go, ThermoFisher).

Immune infiltration analysis

The set of marker genes for 28 immune-related cells and types were collected from Jia et al. [40]. The ssGSEA method of the Gene Set Variation Analysis (GSVA) package was applied to analyze the infiltration level of different immune cells in high CRG-score and low-CRGs score expression profile data.

Statistical analysis

Data was exhibited as mean ± SD. Pearson’s correlation test was used to assess the correlation between CRGs expression levels in ESCA samples. Levene test was used to assess the variance homogeneity of data in different groups. Student t tests or Wilcoxon tests were utilized to estimate the significance between the two groups. In addition, Kruskal-Wallis’s test was used for comparing more than two variables in this study (Fig. 1D). Significance between Kaplan-Meier survival curves was determined with the log-rank test. Univariate Cox regression analysis was used to estimate the hazard ratio (HR) and 95% confidence interval (95% CI). Mann-Whitney U test was employed to compare the number of somatic mutations. All statistical analysis were performed with R (v 4.1.0). p < 0.05 is considered to be a statistically significant.

Supplementary information

Supplemental Table Legends (10.3KB, docx)
Gene symbol list (11.7KB, docx)
The sequence of siRNA (11.4KB, docx)
Primers for PCR (11.2KB, docx)

Author contributions

TJ, FZ, QS, and RMJ conceived and designed the project. RMJ, YH, and YL performed most experiments. RMJ, YL, and XYG performed the bioinformatics analysis; RMJ and YH drew the pictures.; TJ, FZ, QS, and RMJ performed the data interpretation; FZ, TJ, RMJ, and YH wrote the first draft of the manuscript; All authors have read and approved the final manuscript.

Funding

This work was supported by the National Key R&D Program of China (2022YFC3600100, 2019YFA0903801 to QS), the Provincial Key R & D Program of Shaanxi (2021ZDLSF01-08 to TJ), the National Natural Science Foundation of China (81572631 and 31000559 to FZ, 31970685 to QS), Shaanxi Society Development Sci-Tech Research Project (2016SF-064 to FZ), State Key Laboratory of Cancer Biology, Fourth Military Medical University (CBSKL2019ZZ28 to FZ).

Data availability

The datasets in this study are publicly available. They can be found at the location described before. Briefly, TCGA database: https://portal.gdc.cancer.gov/; UCSC Xena server: http://xenabrowser.net/; GEPIA2: http://gepia2.cancer-pku.cn/; Human Protein Atlas database: http://www.proteinatlas.org/; GDSC database: http://www.cancerrxgene.org/. IMvigor210 (mUC) dataset: http://research-pub.gene.com/IMvigor210CoreBiologies/.

Code availability

Original code for figures in the paper are available upon request.

Competing interests

The authors declare no competing interests.

Footnotes

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

These authors contributed equally: Runmin Jiang, Yu Huan, Yan Li.

Contributor Information

Qiang Sun, Email: sunq@bmi.ac.cn.

Feng Zhang, Email: zhf1975@fmmu.edu.cn.

Tao Jiang, Email: Jiangtaochest@163.com.

Supplementary information

The online version contains supplementary material available at 10.1038/s41420-022-01164-5.

References

  • 1.Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021;71:209–49. doi: 10.3322/caac.21660. [DOI] [PubMed] [Google Scholar]
  • 2.Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer Statistics, 2021. CA Cancer J Clin. 2021;71:7–33. [DOI] [PubMed]
  • 3.Rustgi AK, El-Serag HB. Esophageal carcinoma. N Engl J Med. 2014;371:2499–509. doi: 10.1056/NEJMra1314530. [DOI] [PubMed] [Google Scholar]
  • 4.Bandmann O, Weiss KH, Kaler SG. Wilson’s disease and other neurological copper disorders. Lancet Neurol. 2015;14:103–13. doi: 10.1016/S1474-4422(14)70190-5. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 5.Gaggelli E, Kozlowski H, Valensin D, Valensin G. Copper homeostasis and neurodegenerative disorders (Alzheimer’s, prion, and Parkinson’s diseases and amyotrophic lateral sclerosis) Chem Rev. 2006;106:1995–2044. doi: 10.1021/cr040410w. [DOI] [PubMed] [Google Scholar]
  • 6.Tsvetkov P, Coy S, Petrova B, Dreishpoon M, Verma A, Abdusamad M, et al. Copper induces cell death by targeting lipoylated TCA cycle proteins. Science. 2022;375:1254–61. doi: 10.1126/science.abf0529. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 7.Su Y, Huang H, Luo T, Zheng Y, Fan J, Ren H, et al. Cell-in-cell structure mediates in-cell killing suppressed by CD44. Cell Disco. 2022;8:35. doi: 10.1038/s41421-022-00387-1. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 8.Zhang Z, Zheng Y, Niu Z, Zhang B, Wang C, Yao X, et al. SARS-CoV-2 spike protein dictates syncytium-mediated lymphocyte elimination. Cell Death Differ. 2021;28:2765–77. doi: 10.1038/s41418-021-00782-3. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 9.Su Y, Ren H, Tang M, Zheng Y, Zhang B, Wang C, et al. Role and dynamics of vacuolar pH during cell-in-cell mediated death. Cell Death Dis. 2021;12:119. doi: 10.1038/s41419-021-03396-2. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 10.Huang H, Chen Z, Sun Q. Mammalian cell competitions, cell-in-cell phenomena and their biomedical implications. Curr Mol Med. 2015;15:852–60. doi: 10.2174/1566524015666151026101101. [DOI] [PubMed] [Google Scholar]
  • 11.Liang J, Niu Z, Zhang B, Yu X, Zheng Y, Wang C, et al. p53-dependent elimination of aneuploid mitotic offspring by entosis. Cell Death Differ. 2021;28:799–813. doi: 10.1038/s41418-020-00645-3. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 12.Galluzzi L, Vitale I, Aaronson SA, Abrams JM, Adam D, Agostinis P, et al. Molecular mechanisms of cell death: Recommendations of the nomenclature committee on cell death 2018. Cell Death Differ. 2018;25:486–541. doi: 10.1038/s41418-017-0012-4. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 13.O’Day SJ, Eggermont AMM, Chiarion-Sileni V, Kefford R, Grob JJ, Mortier L, et al. Final results of phase III SYMMETRY study: Randomized, double-blind trial of elesclomol plus paclitaxel versus paclitaxel alone as treatment for chemotherapy-naive patients with advanced melanoma. J Clin Oncol. 2013;31:1211–8. doi: 10.1200/JCO.2012.44.5585. [DOI] [PubMed] [Google Scholar]
  • 14.Xu WK, Byun H, Dudley JP. The Role of APOBECs in Viral Replication. Microorganisms. 2020;8:1899. [DOI] [PMC free article] [PubMed]
  • 15.Elango R, Osia B, Harcy V, Malc E, Mieczkowski PA, Roberts SA, et al. Repair of base damage within break-induced replication intermediates promotes kataegis associated with chromosome rearrangements. Nucleic Acids Res. 2019;47:9666–84. doi: 10.1093/nar/gkz651. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 16.Shi M-J, Meng X-Y, Fontugne J, Chen C-L, Radvanyi F, Bernard-Pierrot I. Identification of new driver and passenger mutations within APOBEC-induced hotspot mutations in bladder cancer. Genome Med. 2020;12:85. doi: 10.1186/s13073-020-00781-y. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 17.Yamaguchi H, Hsu J-M, Yang W-H, Hung M-C. Mechanisms regulating PD-L1 expression in cancers and associated opportunities for novel small-molecule therapeutics. Nat Rev Clin Oncol. 2022;19:287–305. doi: 10.1038/s41571-022-00601-9. [DOI] [PubMed] [Google Scholar]
  • 18.Juloski JT, Rakic A, Ćuk VV, Ćuk VM, Stefanović S, Nikolić D, et al. Colorectal cancer and trace elements alteration. J Trace Elem Med Biol. 2020;59:126451. doi: 10.1016/j.jtemb.2020.126451. [DOI] [PubMed] [Google Scholar]
  • 19.Zowczak M, Iskra M, Torliński L, Cofta S. Analysis of serum copper and zinc concentrations in cancer patients. Biol Trace Elem Res. 2001;82:1–8. doi: 10.1385/BTER:82:1-3:001. [DOI] [PubMed] [Google Scholar]
  • 20.Saleh SAK, Adly HM, Abdelkhaliq AA, Nassir AM. Serum Levels of Selenium, Zinc, Copper, Manganese, and Iron in Prostate Cancer Patients. Curr Urol. 2020;14:44–9. doi: 10.1159/000499261. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 21.Khoshdel Z, Naghibalhossaini F, Abdollahi K, Shojaei S, Moradi M, Malekzadeh M. Serum Copper and Zinc Levels Among Iranian Colorectal Cancer Patients. Biol Trace Elem Res. 2016;170:294–9. doi: 10.1007/s12011-015-0483-4. [DOI] [PubMed] [Google Scholar]
  • 22.Lelièvre P, Sancey L, Coll J-L, Deniaud A, Busser B. The multifaceted roles of copper in cancer: A Trace metal element with dysregulated metabolism, but Also a Target or a Bullet for Therapy. Cancers (Basel). 2020;12:3594. [DOI] [PMC free article] [PubMed]
  • 23.Callejón-Leblic B, Gómez-Ariza JL, Pereira-Vega A, García-Barrera T. Metal dyshomeostasis based biomarkers of lung cancer using human biofluids. Metallomics. 2018;10:1444–51. doi: 10.1039/C8MT00139A. [DOI] [PubMed] [Google Scholar]
  • 24.Blockhuys S, Malmberg P, Wittung-Stafshede P. Copper distribution in breast cancer cells detected by time-of-flight secondary ion mass spectrometry with delayed extraction methodology. Biointerphases. 2018;13:06E412. doi: 10.1116/1.5053814. [DOI] [PubMed] [Google Scholar]
  • 25.Yang K, Lu X-F, Luo P-C, Zhang J. Identification of six potentially long noncoding RNAs as biomarkers involved competitive endogenous RNA in clear cell renal cell carcinoma. Biomed Res Int. 2018;2018:9303486. doi: 10.1155/2018/9303486. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 26.Tian H, Ye X, Hou X, Yang X, Yang J, Wu C. SVCT2, a potential therapeutic target, protects against oxidative stress during ethanol-induced neurotoxicity via JNK/p38 MAPKs, NF-κB and miRNA125a-5p. Free Radic Biol Med. 2016;96:362–73. doi: 10.1016/j.freeradbiomed.2016.03.039. [DOI] [PubMed] [Google Scholar]
  • 27.El Ayadi A, Salsbury JR, Enkhbaatar P, Herndon DN, Ansari NH. Metal chelation attenuates oxidative stress, inflammation, and vertical burn progression in a porcine brass comb burn model. Redox Biol. 2021;45:102034. doi: 10.1016/j.redox.2021.102034. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 28.Casabonne D, Gracia E, Espinosa A, Bustamante M, Benavente Y, Robles C, et al. Fruit and vegetable intake and vitamin C transporter gene (SLC23A2) polymorphisms in chronic lymphocytic leukaemia. Eur J Nutr. 2017;56:1123–33. doi: 10.1007/s00394-016-1162-8. [DOI] [PubMed] [Google Scholar]
  • 29.Wright ME, Andreotti G, Lissowska J, Yeager M, Zatonski W, Chanock SJ, et al. Genetic variation in sodium-dependent ascorbic acid transporters and risk of gastric cancer in Poland. Eur J Cancer. 2009;45:1824–30. doi: 10.1016/j.ejca.2009.01.027. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 30.Eastlack SC, Dong S, Ivan C, Alahari SK. Suppression of PDHX by microRNA-27b deregulates cell metabolism and promotes growth in breast cancer. Mol Cancer. 2018;17:100. doi: 10.1186/s12943-018-0851-8. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 31.Xiong S, Wang Q, Zheng L, Gao F, Li J. Identification of candidate molecular markers of nasopharyngeal carcinoma by tissue microarray and in situ hybridization. Med Oncol. 2011;28:S341–S8. doi: 10.1007/s12032-010-9727-5. [DOI] [PubMed] [Google Scholar]
  • 32.Cadiñanos J, Llorente JL, de la Rosa J, Villameytide JA, Illán R, Durán NS, et al. Novel germline SDHD deletion associated with an unusual sympathetic head and neck paraganglioma. Head Neck. 2011;33:1233–40. doi: 10.1002/hed.21384. [DOI] [PubMed] [Google Scholar]
  • 33.Lavilla I, Costas M, Miguel PS, Millos J, Bendicho C. Elemental fingerprinting of tumorous and adjacent non-tumorous tissues from patients with colorectal cancer using ICP-MS, ICP-OES and chemometric analysis. Biometals. 2009;22:863–75. doi: 10.1007/s10534-009-9231-6. [DOI] [PubMed] [Google Scholar]
  • 34.Díez M, Arroyo M, Cerdàn FJ, Muñoz M, Martin MA, Balibrea JL. Serum and tissue trace metal levels in lung cancer. Oncology. 1989;46:230–4. doi: 10.1159/000226722. [DOI] [PubMed] [Google Scholar]
  • 35.Majumder S, Chatterjee S, Pal S, Biswas J, Efferth T, Choudhuri SK. The role of copper in drug-resistant murine and human tumors. Biometals. 2009;22:377–84. doi: 10.1007/s10534-008-9174-3. [DOI] [PubMed] [Google Scholar]
  • 36.Zhou B, Guo L, Zhang B, Liu S, Zhang K, Yan J, et al. Disulfiram combined with copper induces immunosuppression via PD-L1 stabilization in hepatocellular carcinoma. Am J Cancer Res. 2019;9:2442–55. [PMC free article] [PubMed] [Google Scholar]
  • 37.Simoni Y, Becht E, Fehlings M, Loh CY, Koo S-L, Teng KWW, et al. Bystander CD8 T cells are abundant and phenotypically distinct in human tumour infiltrates. Nature. 2018;557:575–9. doi: 10.1038/s41586-018-0130-2. [DOI] [PubMed] [Google Scholar]
  • 38.Meier SL, Satpathy AT, Wells DK. Bystander T cells in cancer immunology and therapy. Nat Cancer. 2022;3:143–55. doi: 10.1038/s43018-022-00335-8. [DOI] [PubMed] [Google Scholar]
  • 39.Zhou L, Niu Z, Wang Y, Zheng Y, Zhu Y, Wang C, et al. Senescence as a dictator of patient outcomes and therapeutic efficacies in human gastric cancer. Cell Death Disco. 2022;8:13. doi: 10.1038/s41420-021-00769-6. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 40.Jia Q, Wu W, Wang Y, Alexander PB, Sun C, Gong Z, et al. Local mutational diversity drives intratumoral immune heterogeneity in non-small cell lung cancer. Nat Commun. 2018;9:5361. doi: 10.1038/s41467-018-07767-w. [DOI] [PMC free article] [PubMed] [Google Scholar]

Associated Data

This section collects any data citations, data availability statements, or supplementary materials included in this article.

Supplementary Materials

Supplemental Table Legends (10.3KB, docx)
Gene symbol list (11.7KB, docx)
The sequence of siRNA (11.4KB, docx)
Primers for PCR (11.2KB, docx)

Data Availability Statement

The datasets in this study are publicly available. They can be found at the location described before. Briefly, TCGA database: https://portal.gdc.cancer.gov/; UCSC Xena server: http://xenabrowser.net/; GEPIA2: http://gepia2.cancer-pku.cn/; Human Protein Atlas database: http://www.proteinatlas.org/; GDSC database: http://www.cancerrxgene.org/. IMvigor210 (mUC) dataset: http://research-pub.gene.com/IMvigor210CoreBiologies/.

Original code for figures in the paper are available upon request.

Articles from Cell Death Discovery are provided here courtesy of Nature Publishing Group

RESOURCES